Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler

被引:51
作者
Kaialy, Waseem [2 ,3 ]
Momin, Mohammed N. [2 ]
Ticehurst, Martyn D. [4 ]
Murphy, John [4 ]
Nokhodchi, Ali [1 ,2 ,5 ,6 ]
机构
[1] Univ Kent, Medway Sch Pharm, Chem & Drug Delivery Grp, Chatham ME4 4TB, Kent, England
[2] Univ Greenwich, Chatham ME4 4TB, Kent, England
[3] Univ Damascus, Pharmaceut & Pharmaceut Technol Dept, Damascus, Syria
[4] Pfizer Global R&D, Pharmaceut Sci, Sandwich CT13 9NJ, Kent, England
[5] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran
关键词
Engineered mannitol; Non-solvent precipitation technique; Solid state characterisation; Elongation ratio; Dry powder inhaler; Fine particle fraction; Deposition test; OPTIMAL PARTICLE-SIZE; DRUG-DELIVERY; AEROSOLS; DEPOSITION; LACTOSE; TERBUTALINE; POLYMORPHS; UNIFORMITY; BEHAVIOR;
D O I
10.1016/j.colsurfb.2010.04.016
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
In this research mannitol particles were prepared by recrystallisation using non-solvent precipitation technique to investigate the effect of engineered carrier particles on their physicochemical properties and the in vitro deposition profiles of a model drug (salbutamol sulphate (SS)) from a dry powder inhaler (DPI). To this end, mannitol aqueous solution (15%, w/v) was added to different ratios of ethanol:water (100:0, 95:5, 90:10 and 85:15) to obtain mannitol particles. These crystallised mannitol particles were analysed in terms of micromeritic properties, morphology, DSC, FT-IR, and in vitro fine particle fraction (FPF) and emitted dose (ED) of SS. The results showed that the elongation ratio of all the recrystallised mannitol batches was higher than the original material giving them a needle-shaped morphology. Salbutamol sulphate deposition profiles from DPI formulation containing recrystallised needle-shaped mannitol showed enhanced performance and better delivery to the lower MSLI stages. The FPF increased from 15.4 +/- 1.1 to 45.8 +/- 0.7% when the commercial mannitol was replaced by mannitol crystallised from ethanol water (90:10). This improvement could be due to the presence of elongated mannitol crystals in formulation blends. Solid state characterisation of engineered mannitol showed that the commercial mannitol was beta-form, mannitol recrystallised from ethanol:water (85:15) was alpha-form and that samples recrystallised in presence of pure ethanol or other ratios of ethanol:water (95:5 and 90:10) were the mixtures of alpha-, beta- and delta-forms. Multi-solvent recrystallisation technique was proved to have potential to produce mannitol crystals suitable for enhanced aerosolisation efficiency. Comparing different crystallised mannitol formulations showed that the final form (the type of polymorph) of the crystallised mannitol does not have a substantial effect on salbutamol sulphate aerosolisation performance. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:345 / 356
页数:12
相关论文
共 35 条
[21]   Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry - exploring preferred orientation effects [J].
Roberts, SNC ;
Williams, AC ;
Grimsey, IM ;
Booth, SW .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1149-1159
[22]   General principles of pharmaceutical solid polymorphism:: a supramolecular perspective [J].
Rodríguez-Spong, B ;
Price, CP ;
Jayasankar, A ;
Matzger, AJ ;
Rodriguez-Hornedo, N .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (03) :241-274
[23]   On the relationship between drug and carrier deposition from dry powder inhalers in vitro [J].
Srichana, T ;
Martin, GP ;
Marriott, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 167 (1-2) :13-23
[24]   HUMAN RESPIRATORY DEPOSITION OF PARTICLES DURING ORONASAL BREATHING [J].
SWIFT, DL ;
PROCTOR, DF .
ATMOSPHERIC ENVIRONMENT, 1982, 16 (09) :2279-2282
[25]   Drug delivery to the small airways [J].
Thompson, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (05) :S199-S202
[26]   DRUG-DELIVERY TO THE RESPIRATORY-TRACT USING DRY POWDER INHALERS [J].
TIMSINA, MP ;
MARTIN, GP ;
MARRIOTT, C ;
GANDERTON, D ;
YIANNESKIS, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 101 (1-2) :1-13
[27]  
*US PHARM CONV INC, 2003, 26NF21 USP US PHARM, P2114
[28]   Crystalline solids [J].
Vippagunta, SR ;
Brittain, HG ;
Grant, DJW .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 48 (01) :3-26
[29]  
WALTERLEVY L, 1968, CR ACAD SCI C CHIM, V267, P1779
[30]   Moisture induced polymorphic transition of mannitol and its morphological transformation [J].
Yoshinari, T ;
Forbes, RT ;
York, P ;
Kawashima, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 247 (1-2) :69-77